中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 11
Nov.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(11): 2444-2447

Anti-HBV therapy timing and drug selection in various populations

DOI: 10.3969/j.issn.1001-5256.2022.11.002
  • 1.

    Department of infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China

  • 2.

    Second School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong 264003, China

More Information
  • Corresponding author: PENG Liang, pliang@mail.sysu.edu.cn(ORCID: 0000-0001-6184-5750)
  • Received Date: 2022-06-22
  • Accepted Date: 2022-07-26
  • Published Date: 2022-11-20
    Abstract
  • Hepatitis B virus (HBV) infection is still a serious disease threatening human health. Anti-HBV treatment is an extremely important means to reduce the threat of hepatitis B. In recent years, there has been no consensus on the timing and drug selection of anti-HBV therapy. The timing and drug selection of anti-HBV therapy in various populations are discussed in this article.

     

    • FullText(HTML)
  • loading
    • References(36)
  • [1]
    LIU J, LIANG W, JING W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
    [2]
    European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
    [3]
    TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
    [4]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [5]
    KUMAR M, SARIN SK, HISSAR S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology, 2008, 134(5): 1376-1384. DOI: 10.1053/j.gastro.2008.02.075.
    [6]
    CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311.
    [7]
    LIU J, WANG J, YAN X, et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal alt and detectable HBV DNA in absence of liver fibrosis[J]. Hepatol Commun, 2022, 6(4): 855-866. DOI: 10.1002/hep4.1859.
    [8]
    MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151(5): 986-998.e4. DOI: 10.1053/j.gastro.2016.07.012.
    [9]
    CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.
    [10]
    KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
    [11]
    CHANG Y, CHOE WH, SINN DH, et al. Nucleos(t)ide analogue treatment for patients with hepatitis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A nationwide, multicenter, retrospective study[J]. J Infect Dis, 2017, 216(11): 1407-1414. DOI: 10.1093/infdis/jix506.
    [12]
    LEE HW, KIM EH, LEE J, et al. Natural history of untreated HBeAg-positive chronic HBV infection with persistently elevated HBV DNA but normal alanine aminotransferase[J]. Clin Transl Gastroenterol, 2020, 11(3): e00140. DOI: 10.14309/ctg.0000000000000140.
    [13]
    JEON MY, KIM BK, LEE JS, et al. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B[J]. Clin Mol Hepatol, 2021, 27(2): 295-304. DOI: 10.3350/cmh.2020.0216.
    [14]
    LEE HA, LEE HW, KIM IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase[J]. Aliment Pharmacol Ther, 2020, 52(1): 196-204. DOI: 10.1111/apt.15741.
    [15]
    WANG L, WU L, LI X, et al. Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial[J]. BMJ Open, 2021, 11(8): e048410. DOI: 10.1136/bmjopen-2020-048410.
    [16]
    CHAN HL, CHAN CK, HUI AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA[J]. Gastroenterology, 2014, 146(5): 1240-1248. DOI: 10.1053/j.gastro.2014.01.044.
    [17]
    ZHU S, ZHANG H, DONG Y, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study[J]. J Hepatol, 2018, 68(6): 1123-1128. DOI: 10.1016/j.jhep.2018.01.037.
    [18]
    CAO Z, LIU Y, MA L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66(4): 1058-1066. DOI: 10.1002/hep.29213.
    [19]
    GAO WK, SHU YY, CHEN Y, et al. Effectiveness of Tenofovir Alafenamide in chronic hepatitis B patients with normal alanine aminotransferase and positive hepatitis B virus DNA[J]. J Clin Transl Hepatol, 2022, 10(1): 112-119. DOI: 10.14218/JCTH.2021.00131.
    [20]
    WANG FD, ZHOU J, ZHANG DM, et al. A study of the effectiveness of nucleos(t)ide analogues in the treatment of HBeAg-positive chronic hepatitis B with normal alanine aminotransferase and high level of HBV DNA[J]. Chin J Hepatol, 2022, 30(4): 389-394. DOI: 10.3760/cma.j.cn501113-20210705-00318.

    王发达, 周静, 张冬梅, 等. 核苷(酸)类似物治疗丙氨酸转氨酶正常HBeAg阳性且HBV DNA高水平慢性乙型肝炎的有效性研究[J]. 中华肝脏病杂志, 2022, 30(4): 389-394. DOI: 10.3760/cma.j.cn501113-20210705-00318.
    [21]
    UDOMPAP P, KIM D, AHMED A, et al. Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment[J]. Aliment Pharmacol Ther, 2018, 48(11-12): 1282-1289. DOI: 10.1111/apt.15020.
    [22]
    LAI KN, LI PK, LUI SF, et al. Membranous nephropathy related to hepatitis B virus in adults[J]. N Engl J Med, 1991, 324(21): 1457-1463. DOI: 10.1056/NEJM199105233242103.
    [23]
    CAI D, PAN C, YU W, et al. Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials[J]. Medicine (Baltimore), 2019, 98(1): e13983. DOI: 10.1097/MD.0000000000013983.
    [24]
    LÓPEZ CENTENO B, COLLADO BORRELL R, PÉREZ ENCINAS M, et al. Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B[J]. Farm Hosp, 2016, 40(4): 279-286. DOI: 10.7399/fh.2016.40.4.10492.
    [25]
    AGARWAL K, FUNG SK, NGUYEN TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection[J]. J Hepatol, 2015, 62(3): 533-540. DOI: 10.1016/j.jhep.2014.10.035.
    [26]
    AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68(4): 672-681. DOI: 10.1016/j.jhep.2017.11.039.
    [27]
    OGAWA E, NOMURA H, NAKAMUTA M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B[J]. Liver Int, 2020, 40(7): 1578-1589. DOI: 10.1111/liv.14482.
    [28]
    FARAG MS, FUNG S, TAM E, et al. Effectiveness and renal safety of Tenofovir Alafenamide fumarate among chronic hepatitis B patients: Real-world study[J]. J Viral Hepat, 2021, 28(6): 942-950. DOI: 10.1111/jvh.13500.
    [29]
    LAMPERTICO P, BUTI M, FUNG S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study[J]. Lancet Gastroenterol Hepatol, 2020, 5(5): 441-453. DOI: 10.1016/S2468-1253(19)30421-2.
    [30]
    de FRAGA RS, van VAISBERG V, MENDES L, et al. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review[J]. J Gastroenterol, 2020, 55(5): 496-514. DOI: 10.1007/s00535-020-01680-0.
    [31]
    NGUYEN MH, LIM JK, BURAK OZBAY A, et al. Advancing age and comorbidity in a US insured population-based cohort of patients with chronic hepatitis B[J]. Hepatology, 2019, 69(3): 959-973. DOI: 10.1002/hep.30246.
    [32]
    YU MW, LIN CL, LIU CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: A large cohort study[J]. Gastroenterology, 2017, 153(4): 1006-1017.e5. DOI: 10.1053/j.gastro.2017.07.001.
    [33]
    SANTOS JR, SAUMOY M, CURRAN A, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial[J]. Clin Infect Dis, 2015, 61(3): 403-408. DOI: 10.1093/cid/civ296.
    [34]
    LI ZB, LI L, NIU XX, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia[J]. Liver Int, 2021, 41(6): 1254-1264. DOI: 10.1111/liv.14786.
    [35]
    BYUN KS, CHOI J, KIM JH, et al. Tenofovir Alafenamide for drug-resistant hepatitis B: A randomized trial for switching from tenofovir disoproxil fumarate[J]. Clin Gastroenterol Hepatol, 2022, 20(2): 427-437.e5. DOI: 10.1016/j.cgh.2021.04.045.
    [36]
    ZHANG Y, LI Z, LUO Q, et al. Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study[J]. Antivir Ther, 2022, 27 (2): 135965352210823. DOI: 10.1177/13596535221082399.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (901) PDF downloads(216) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return